Skip to main content
. 2013 Apr 2;13:176. doi: 10.1186/1471-2407-13-176

Figure 7.

Figure 7

Expression of Notch-1, Notch-3 and its downstream target HES-1 in tumor tissue. Influence of CPA treatment on expression levels of Notch-3, Notch-1 and its downstream target HES-1 were determined in tumor tissue by qRT-PCR analysis before and after two treatments (HUH-PAS and HUH-REISO) and further four treatments in the case of HUH-REISO (n=5). (A) In contrast to significant induction of Notch-1 expression by two CPA therapies in passaged tumors (HUH-PAS), Notch-1 expression levels in chemoresistant tumors (HUH-REISO) remained not significantly altered even after further four CPA-treatments. Initial expression levels of Notch-1 were not significantly different. (B) HES-1 expression levels were detected to be significantly induced after two treatments for passaged (HUH-PAS) and chemoresistant tumors (HUH-REISO). Initial expression levels and expression levels after two CPA-treatments remained significantly low compared to tumors grown from in vivo passaged cells (HUH-PAS). After further four treatments, expression levels again reached initial HES-1 expression in chemoresistant tumors (HUH-REISO). (C) Notch-3 showed in both groups HUH-PAS (p=0.0247) and HUH-REISO (p=0.0446) significantly upregulated levels after two times of CPA therapy. After additional four CPA treatments, level of Notch-3 in HUH-REISO dropped back on base levels.